AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
211.92
+1.52 (0.72%)
At close: Sep 2, 2025, 4:00 PM
211.49
-0.43 (-0.20%)
After-hours: Sep 2, 2025, 5:00 PM EDT
AbbVie Revenue
AbbVie had revenue of $15.42B in the quarter ending June 30, 2025, with 6.65% growth. This brings the company's revenue in the last twelve months to $58.33B, up 6.05% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$58.33B
Revenue Growth
+6.05%
P/S Ratio
6.38
Revenue / Employee
$1,060,509
Employees
55,000
Market Cap
374.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
ABBV News
- 9 hours ago - AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - PRNewsWire
- 3 days ago - How To Invest $100,000 In A Near-Perfect Strategy Portfolio - Seeking Alpha
- 4 days ago - AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin - Seeking Alpha
- 5 days ago - Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy. - Barrons
- 6 days ago - Best Dividend Aristocrats For September 2025 - Seeking Alpha
- 7 days ago - AbbVie: Plenty Of Positives - Seeking Alpha
- 8 days ago - AbbVie Is A Top Biotech Pick - Seeking Alpha
- 8 days ago - AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion - Reuters